LONDON, Jan 7 (Reuters) – GSK’s experimental drug to treat chronic hepatitis B infection met the main goals in two closely watched studies, the drugmaker said on Wednesday, bringing the company a step closer to making a functional cure available to patients.
(Reporting by Bhanvi Satija and Pushkala Aripaka in Bengaluru; Editing by Subhranshu Sahu)
